论文部分内容阅读
目的:探讨ATG加CsA方案治疗重型再生障碍性贫血(再障)的疗效、疗程和治疗相关并发症。方法:对56例重型再障给予ATG加CsA方案治疗,每月至少观察一次血常规、肝、肾功能等项目。结果:56例中完全反应45例(80%),部分反应5例(9%),无效6例(11%)。复发10例(20%)。结论:ATG加CsA治疗重型再障疗效好、并发症可防可治,主要不足是疗程长。
Objective: To investigate the efficacy, duration of treatment and treatment-related complications of ATG plus CsA regimen in the treatment of severe aplastic anemia (AA). Methods: 56 cases of severe aplastic anemia given ATG plus CsA regimen, observed at least once a month blood routine, liver, kidney function and other items. Results: Of the 56 patients, 45 (80%) completely responded, 5 (9%) partially responded, and 6 (11%) ineffective. Recurrent in 10 cases (20%). CONCLUSION: ATG plus CsA is effective in treating severe aplastic anemia. The complication can be prevented and cured. The main problem is long course of treatment.